Results 291 to 300 of about 1,125,486 (341)
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Correction: Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights. [PDF]
PLoS OneManzoor H +5 more
europepmc +1 more source
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
Molecular Oncology, EarlyView.p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
Computational evaluation of AKT2 mutations reveals R274H and R467W as potential drivers of protein instability and inhibitor resistance in cancer therapy. [PDF]
PLoS OneRuna SA, Tonmoy MIQ, Islam MA, Islam MA.
europepmc +1 more source
Risk of genitourinary late effects after radiotherapy for prostate cancer associated with early changes in bladder shape. [PDF]
Phys Imaging Radiat OncolCasares-Magaz O +8 more
europepmc +1 more source
A remark on compact symplectic manifolds not admitting complex structures
, 1990 Marisa Fernández +2 more
openalex +1 more source